Last reviewed 2026-05-13 · How we verify

THERATOPE STn-KLH vaccine

Oncothyreon Canada Inc. · Phase 3 active Biologic

THERATOPE STn-KLH vaccine is a vaccine Biologic drug developed by Oncothyreon Canada Inc.. It is currently in Phase 3 development for Non-small cell lung cancer.

The THERATOPE STn-KLH vaccine works by stimulating an immune response against the STn antigen, which is expressed on the surface of cancer cells.

The THERATOPE STn-KLH vaccine works by stimulating an immune response against the STn antigen, which is expressed on the surface of cancer cells. Used for Non-small cell lung cancer.

At a glance

Generic name	THERATOPE STn-KLH vaccine
Sponsor	Oncothyreon Canada Inc.
Drug class	vaccine
Target	STn antigen
Modality	Biologic
Therapeutic area	Oncology
Phase	Phase 3

Mechanism of action

This vaccine is designed to induce the production of antibodies that can recognize and bind to the STn antigen, marking cancer cells for destruction by the immune system. The STn antigen is a tumor-associated antigen that is overexpressed on the surface of many types of cancer cells, making it a promising target for immunotherapy.

Approved indications

Non-small cell lung cancer

Common side effects

Fatigue
Pain
Nausea
Vomiting
Diarrhea

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

THERATOPE STn-KLH vaccine CI brief — competitive landscape report
THERATOPE STn-KLH vaccine updates RSS · CI watch RSS
Oncothyreon Canada Inc. portfolio CI

Frequently asked questions about THERATOPE STn-KLH vaccine

What is THERATOPE STn-KLH vaccine?

THERATOPE STn-KLH vaccine is a vaccine drug developed by Oncothyreon Canada Inc., indicated for Non-small cell lung cancer.

How does THERATOPE STn-KLH vaccine work?

The THERATOPE STn-KLH vaccine works by stimulating an immune response against the STn antigen, which is expressed on the surface of cancer cells.

What is THERATOPE STn-KLH vaccine used for?

THERATOPE STn-KLH vaccine is indicated for Non-small cell lung cancer.

Who makes THERATOPE STn-KLH vaccine?

THERATOPE STn-KLH vaccine is developed by Oncothyreon Canada Inc. (see full Oncothyreon Canada Inc. pipeline at /company/oncothyreon-canada-inc).

What drug class is THERATOPE STn-KLH vaccine in?

THERATOPE STn-KLH vaccine belongs to the vaccine class. See all vaccine drugs at /class/vaccine.

What development phase is THERATOPE STn-KLH vaccine in?

THERATOPE STn-KLH vaccine is in Phase 3.

What are the side effects of THERATOPE STn-KLH vaccine?

Common side effects of THERATOPE STn-KLH vaccine include Fatigue, Pain, Nausea, Vomiting, Diarrhea.

What does THERATOPE STn-KLH vaccine target?

THERATOPE STn-KLH vaccine targets STn antigen and is a vaccine.

Drug class: All vaccine drugs
Target: All drugs targeting STn antigen
Manufacturer: Oncothyreon Canada Inc. — full pipeline
Therapeutic area: All drugs in Oncology
Indication: Drugs for Non-small cell lung cancer
Compare: THERATOPE STn-KLH vaccine vs similar drugs
Pricing: THERATOPE STn-KLH vaccine cost, discount & access